retatrutide safety study Efficacy and of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 Retatrutide Peptide Safety and Access

Typical injection site reactions include temporary redness extending one to three centimeters from the injection point, mild warmth or tenderness lasting a few hours to a day, slight swelling that resolves within 24 to 48 hours, and occasional itching limited to the immediate area

Current for 2025, this guide synthesizes the latest AWARD-11 trial data, includes up-to-date drug-to-drug comparisons (Ozempic, Wegovy, Zepbound), and offers practical tips for maximizing resultswhether your goal is better A1C, a smaller waistline, or both

We provide continuous support for nutrition, mindset, and exercise to keep you accountable and motivated

Pandis, DNP, APRN, FNP-C Share : Share : 1

It does not raise IGF-1 levels